Sign In for increased benefits
Turn your one-off questions into a powerhouse research hub.
🚨
Real-time alerts on your custom watchlists
🔍
Unlock Deep Research Mode
📊
Exportable PDF/Word reports
📚
Revisit every question in your account history
⭐
Get personalised research and news based on your past questions
🤝
Team collaborate & annotate insights
🌐
Sync across devices—never lose your place
👑
Early-access to the next big AI features
📚
Continue enjoying 40 questions daily on your free account
Maybe Later
Sign In Now
About Us
FAQs
Contact Us
Privacy Policy
Cookies Policy
Terms and Condition
Acceptable Use Policy
Data Processing Addendum
📢
New Earnings
In
!
🔍
Dafinchi
Sign In
Latest Earnings
Earnings Chat
Earnings Feed
Companies
Earnings Feed
Hide Filters
Quantum-Si incorporated
QSI
2025 Q2
Healthcare
1w
Impact of NIH Funding and Capital Market Headwinds on Revenue
Second quarter revenue was $591,000, below expectations due to halt in capital purchases by U.S. academic labs.
Full impact of NIH funding uncertainties was felt in Q2, affecting capital sales.
Despite short-term headwinds, pharma and biotech segments show growth potential with increased funnel of opportunities.
Management emphasizes the importance of growing installed base for long-term value and consumable sales.
Explore Similar Insights
Day One Biopharmaceuticals, Inc.
DAWN
2025 Q2
Healthcare
1w
OJEMDA 12-Month Revenue Exceeds Expectations
OJEMDA has generated $113.1 million in net revenue over the past 12 months, surpassing initial expectations.
The company reports strong commercial momentum, physician adoption, and patient demand.
Ongoing growth driven by deepening prescriber adoption and payer coverage.
Dafinchi